(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) presented new efficacy and safety data for ecopipam, an investigational, first-in-class selective dopamine D1 receptor antagonist being developed for pediatric patients with Tourette syndrome.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.